期刊文献+

EGFR/HER2联合多肽表位疫苗的构建及体液免疫学分析 被引量:3

Construction and immunological analysis of a combined multi-epitope vaccine against EGFR/HER2
原文传递
导出
摘要 构建以乙肝病毒核心抗原(HBcAg)为载体的带有1个EGFR和2个HER2的模拟B细胞表位多肽的融合表达质粒pET28a/HBcAg-△n,表达出融合蛋白并纯化,通过免疫BALB/c小鼠获得抗目的蛋白的抗体。采用PCR法将3个模拟表位插入HBc序列的第78~79位,再将该序列克隆入pET28a载体中,构建重组表达质粒,用大肠杆菌BL21(DE3)作宿主菌表达出融合蛋白HBHE,纯化后免疫BALB/c小鼠,检测小鼠的体液免疫应答。测序结果表明,重组质粒构建成功,SDS-PAGE电泳显示融合蛋白表达正确,ELISA检测到高滴度抗体。以HBcAg为载体的B表位被成功表达和纯化,获得高滴度的与3个B表位结合的抗体,为进一步研究HER家族成员联合多肽表位疫苗的广谱抗肿瘤作用奠定了基础。 A recombinant plasmid pET28a-HBcAg-△n was constructed,in which three mimic B-epitopes of HER family were inserted into the truncated HBc vector.The fusion protein expressed was purified and used to immunize BALB/c mice to induce antibody against the epitopes.Three mimic epitope genes were inserted into the sequences of amino acid residues 78 and 79 of HBcAg by overlap PCR.The PCR product was then cloned into pET28a to construct recombinant expression plasmid which was transformed to E.coli BL21(DE3) and induced by IPTG.After purification,the fused protein designed HBHE was used to immunize BALB/c mice to detect humoral immunoresponse.The recombinant plasmid was successfully constructed by DNA sequencing analysis.A fusion protein with correct molecular mass was expressed and confirmed by SDS-PAGE.High titre antibody was elicited in the mice immunized with HBHE by indirect ELISA and Western blotting.The HBc particle vector containing three B-epitopes of HER family had been successfully prepared,purified and high titre antibody against HBHE was detected.All these data are helpful in further research of the broad-spectrum anti-tumour effect of combine polypeptide epi-position vaccine of EGFR and HER2.
出处 《药学学报》 CAS CSCD 北大核心 2011年第11期1326-1331,共6页 Acta Pharmaceutica Sinica
基金 江苏省自然科学基金资助项目(BK2009456)
关键词 EGFR HER2 B表位 HBCAG 疫苗 EGFR HER2 B-epitope HBcAg vaccine
  • 相关文献

参考文献3

二级参考文献41

  • 1徐丽慧,洪岸,何贤辉.人EGF受体胞外域cDNA克隆及其序列分析[J].暨南大学学报(自然科学与医学版),2005,26(2):168-173. 被引量:6
  • 2徐丽慧,洪岸,何贤辉,汪炬.重组人bFGF的原核表达及其高效价抗血清的制备[J].免疫学杂志,2005,21(3):186-189. 被引量:6
  • 3徐丽慧,洪岸,何贤辉.人EGF受体L2结构域在大肠杆菌中表达、包涵体柱上复性及纯化[J].生物工程学报,2005,21(4):597-603. 被引量:5
  • 4Nardin EH, Calvo-Calle JM, Oliveira GA, et al. A totally synthetic polyoxime malaria vaccine containing Plasmodiumfalciparum B cell and universal T cell epitopes elicits immune responses in volunteers of diverse HLA types[J]. J Immunol,2001,166 :481-489.
  • 5Arnon R, Tarrab-Hazdai R, Steward M. A mimotope peptide-based vaccine against Schistosoma mansoni: synthesis and characterization[J]. Immunology ,2000,101:555-562.
  • 6Reynolds SR, Dahl CE, Ham DA. T and B epitope determination and analysis of multiple antigenic peptides for the Schistosoma mansoni experimental vaccine triose-phosphate isomerase[J]. J Immunol, 1994,152: 193-200.
  • 7Huebener N, Lange B, Lemmel C, et al. Vaccination with minigenes encoding for novel ‘ self' antigens are effective in DNA-vaccination against neuroblastoma[J]. Cancer Lett ,2003,197:211-217.
  • 8Williams KM, Bigley EC 3rd, Raybourne RB. Identification of murine B-cell and T-cell epitopes of Escherichia coli outer membrane protein F with synthetic polypeptides[J]. Infect Immun,2000 ,68 :2535-2545.
  • 9Rammensee H, Bachmann J, Emmerich NP, et al. SYFPEITHI:database for MHC ligands and peptide motifs [J]. Immunogenetics, 1999,50:213-219.
  • 10Hagmann M. Computers aid vaccine design [J]. Science, 2000,290: 80-82.

共引文献22

同被引文献14

  • 1科学技术部社会发展科技司.生物医药发展战略报告[M].北京:科学出版社,2009:26.
  • 2Cancer Vaccines Poised to Reach 83 Billion in Sales by 2015 [EB/OL]. http://www.pharmalive.comlsubscriptions/news.cfm?nid= 775555&from=% 2Fnews% 2F% 3Farticleid% 30775555% 26 search%3D1.
  • 3http://www.gsk.com/.
  • 4The President's Budget for Fiscal Year 2012[EB/OL]. http:// www.whitehouse.gov/omb/budget/.
  • 5Burkhardt U E, Sloots A, Jakobi V. IL-15 augments amitumoral activity of an ErbB2/HER2 cancer vaccine targeted to protessional antigen-presenting cells[J]. Cancer Immunol Immunother, 2012,61(9):1473-1484.
  • 6Patil R, Clifton G T, Holmes J P, et al. Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase Ⅰ/Ⅱ clinical trial[J]. J Am Coll Surg, 2010,210(2):140- 147.
  • 7Woll M M, Hueman M T, Ryan G B. Preclinieal testing of a peptide-based, HER2/neu vaccine for prostate cancer[J]. Int J Oncol, 2004,25(6): 1769-1780.
  • 8Shahabi V, Seavey M M, Maciag P C. Development of a live and highly attenuated Listeria monocytogenes-hased vaccine for the treatment of Her2/neu-overexpressing cancers in human [J]. Cancer Gene Ther, 2011,18(1):53-62.
  • 9Mohebtash M. Tsang K Y, Madan R A. A pilot study of MUC-I/CEA/TRICOM poxviral-based vaeeine in patients with metastatic breast and ovarian cancer[J]. Clin Cancer Res, 2011,17(22):7164-7173.
  • 10Madan R A, Arlen P M, Gulley J L. PANVAC-VF: poxvi- ral-based vaccine therapy targeting CEA and MUC1 in carcinoma[J]. Expert Opin Biol Ther, 2007,7(4):543-554.

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部